Video
How Microbiome-based Therapeutics May Impact Treatment Landscape for C. Diff Infection, Recurrent C. Diff Infection
Teena Chopra, MD, MPH, professor of infectious diseases at Wayne State University, discussed how microbiome-based therapeutics may impact the current treatment landscape for C. diff infection and recurrent C. diff infection.
Pharmacy Times interviewed Teena Chopra, MD, MPH, professor of infectious diseases at Wayne State University, on her presentation at the American Society of Health-System Pharmacists 2021 Midyear Clinical Meeting on whether the power of the microbiome can be unlocked to break the cycle of recurrent Clostridioides difficile (C. diff) infection.
During the interview, Chopra discussed how microbiome-based therapeutics may impact the current treatment landscape for C. diff infection and recurrent C. diff infection.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
